BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wermuth PJ, Del Galdo F, Jiménez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009;60:1508-18. [PMID: 19404939 DOI: 10.1002/art.24471] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Elbeshlawi I, Abdelbaki MS. Safety of Gadolinium Administration in Children. Pediatric Neurology 2018;86:27-32. [DOI: 10.1016/j.pediatrneurol.2018.07.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
2 Bernstein EJ, Schmidt-lauber C, Kay J. Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure. Best Practice & Research Clinical Rheumatology 2012;26:489-503. [DOI: 10.1016/j.berh.2012.07.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
3 Fok JS, Smith WB. Hypersensitivity reactions to gadolinium-based contrast agents. Current Opinion in Allergy & Clinical Immunology 2017;17:241-6. [DOI: 10.1097/aci.0000000000000371] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Nazarian RM, Mandal RV, Kagan A, Kay J, Duncan LM. Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: A diagnostic aid. Journal of the American Academy of Dermatology 2011;64:741-7. [DOI: 10.1016/j.jaad.2010.05.034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
5 Perone PA, Weber SL, DaSilva M, Paruchuri T, Bhagavathula N, Aslam MN, Dame MK, Johnson KJ, Swartz RD, Varani J. Collagenolytic activity is suppressed in organ-cultured human skin exposed to a gadolinium-based MRI contrast agent. Invest Radiol 2010;45:42-8. [PMID: 19996758 DOI: 10.1097/RLI.0b013e3181bf95eb] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
6 Chopra T, Kandukurti K, Shah S, Ahmed R, Panesar M. Understanding nephrogenic systemic fibrosis. Int J Nephrol. 2012;2012:912189. [PMID: 23193473 DOI: 10.1155/2012/912189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
7 Davies J, Siebenhandl-Wolff P, Tranquart F, Jones P, Evans P. Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration. Arch Toxicol 2022. [PMID: 34997254 DOI: 10.1007/s00204-021-03189-8] [Reference Citation Analysis]
8 Basak P, Jesmajian S. Nephrogenic systemic fibrosis: current concepts. Indian J Dermatol 2011;56:59-64. [PMID: 21572795 DOI: 10.4103/0019-5154.77555] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
9 Wermuth PJ, Jimenez SA. Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis. J Immunol 2012;189:318-27. [PMID: 22649203 DOI: 10.4049/jimmunol.1103099] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
10 Li J, Liu J, Wang K, Yang X. Gadolinium-containing bioparticles as an active entity to promote cell cycle progression in mouse embryo fibroblast NIH3T3 cells. J Biol Inorg Chem 2010;15:547-57. [DOI: 10.1007/s00775-010-0622-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
11 Stratta P, Canavese C, Quaglia M, Fenoglio R. Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network. Rheumatology (Oxford) 2010;49:821-3. [PMID: 20032228 DOI: 10.1093/rheumatology/kep403] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
12 Li T, Sun M, Yin X, Wu C, Wu Q, Feng S, Li H, Luan Y, Wen J, Yan L, Zhao B, Xu C, Sun Y. Expression of the calcium sensing receptor in human peripheral blood T lymphocyte and its contribution to cytokine secretion through MAPKs or NF-κB pathways. Mol Immunol 2013;53:414-20. [PMID: 23103379 DOI: 10.1016/j.molimm.2012.09.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
13 Bleavins K, Perone P, Naik M, Rehman M, Aslam MN, Dame MK, Meshinchi S, Bhagavathula N, Varani J. Stimulation of fibroblast proliferation by insoluble gadolinium salts. Biol Trace Elem Res 2012;145:257-67. [PMID: 21882070 DOI: 10.1007/s12011-011-9176-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
14 Piera-Velazquez S, Wermuth PJ, Gomez-Reino JJ, Varga J, Jimenez SA. Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis. Semin Arthritis Rheum 2020;50:1226-37. [PMID: 33059296 DOI: 10.1016/j.semarthrit.2020.09.003] [Reference Citation Analysis]
15 Jenkins W, Perone P, Walker K, Bhagavathula N, Aslam MN, DaSilva M, Dame MK, Varani J. Fibroblast response to lanthanoid metal ion stimulation: potential contribution to fibrotic tissue injury. Biol Trace Elem Res 2011;144:621-35. [PMID: 21484406 DOI: 10.1007/s12011-011-9041-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
16 Wermuth PJ, Jimenez SA. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib). PLoS One 2018;13:e0196559. [PMID: 29718973 DOI: 10.1371/journal.pone.0196559] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
17 Wang W, Lazar A. Diseases of collagen and elastic tissue. McKee's Pathology of the Skin. Elsevier; 2012. pp. 935-66. [DOI: 10.1016/b978-1-4160-5649-2.00021-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
18 Haemel AK, Sadowski EA, Shafer MM, Djamali A. Update on nephrogenic systemic fibrosis: are we making progress?: Update on nephrogenic systemic fibrosis. International Journal of Dermatology 2011;50:659-66. [DOI: 10.1111/j.1365-4632.2010.04851.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
19 Richter H, Bücker P, Martin LF, Dunker C, Fingerhut S, Xia A, Karol A, Sperling M, Karst U, Radbruch A, Jeibmann A. Gadolinium Tissue Distribution in a Large-Animal Model after a Single Dose of Gadolinium-based Contrast Agents. Radiology 2021;301:637-42. [PMID: 34546128 DOI: 10.1148/radiol.2021210553] [Reference Citation Analysis]
20 DaSilva M, O'Brien Deming M, Fligiel SE, Dame MK, Johnson KJ, Swartz RD, Varani J. Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol 2010;45:733-9. [PMID: 20661146 DOI: 10.1097/RLI.0b013e3181e9436b] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
21 Idée J, Fretellier N, Robic C, Corot C. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Critical Reviews in Toxicology 2014;44:895-913. [DOI: 10.3109/10408444.2014.955568] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
22 Wermuth PJ, Carney KR, Mendoza FA, Piera-Velazquez S, Jimenez SA. Endothelial cell-specific activation of transforming growth factor-β signaling in mice induces cutaneous, visceral, and microvascular fibrosis. Lab Invest 2017;97:806-18. [PMID: 28346399 DOI: 10.1038/labinvest.2017.23] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
23 Morcos SK. Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far? Eur Radiol 2011;21:496-500. [DOI: 10.1007/s00330-010-1951-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
24 Maecker HT, Siebert JC, Rosenberg-Hasson Y, Koran LM, Ramalho M, Semelka RC. Acute Chelation Therapy-Associated Changes in Urine Gadolinium, Self-reported Flare Severity, and Serum Cytokines in Gadolinium Deposition Disease. Invest Radiol 2021;56:374-84. [PMID: 33449576 DOI: 10.1097/RLI.0000000000000752] [Reference Citation Analysis]
25 Lafyatis R, York M. Innate immunity and inflammation in systemic sclerosis. Curr Opin Rheumatol 2009;21:617-22. [PMID: 19633559 DOI: 10.1097/BOR.0b013e32832fd69e] [Cited by in Crossref: 52] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
26 . Current world literature. Curr Opin Rheumatol 2009;21:656-65. [PMID: 20009876 DOI: 10.1097/BOR.0b013e3283328098] [Reference Citation Analysis]
27 Bardin T, Richette P. Nephrogenic systemic fibrosis. Current Opinion in Rheumatology 2010;22:54-8. [DOI: 10.1097/bor.0b013e328333bf3d] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
28 Haylor J, Schroeder J, Wagner B, Nutter F, Jestin G, Idée J, Morcos S. Skin Gadolinium Following Use of MR Contrast Agents in a Rat Model of Nephrogenic Systemic Fibrosis. Radiology 2012;263:107-16. [DOI: 10.1148/radiol.12110881] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
29 Yildiz S, Cece H, Kaya I, Celik H, Taskin A, Aksoy N, Kocyigit A, Eren MA. Impact of contrast enhanced MRI on lymphocyte DNA damage and serum visfatin level. Clin Biochem 2011;44:975-9. [PMID: 21620817 DOI: 10.1016/j.clinbiochem.2011.05.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
30 Sieber MA, Steger-hartmann T, Lengsfeld P, Pietsch H. Gadolinium-based contrast agents and NSF: Evidence from animal experience. J Magn Reson Imaging 2009;30:1268-76. [DOI: 10.1002/jmri.21971] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 5.6] [Reference Citation Analysis]
31 Gou BD, Bian S, Zhang TL, Wang K. Gadolinium-promoted precipitation of calcium phosphate is associated with profibrotic activation of RAW 264.7 macrophages. Toxicol In Vitro 2010;24:1743-9. [PMID: 20471468 DOI: 10.1016/j.tiv.2010.05.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
32 Maecker HT, Wang W, Rosenberg-Hasson Y, Semelka RC, Hickey J, Koran LM. An initial investigation of serum cytokine levels in patients with gadolinium retention. Radiol Bras 2020;53:306-13. [PMID: 33071374 DOI: 10.1590/0100-3984.2019.0075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 Bhagavathula N, Dame MK, DaSilva M, Jenkins W, Aslam MN, Perone P, Varani J. Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol 2010;45:769-77. [PMID: 20714270 DOI: 10.1097/RLI.0b013e3181e943d2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
34 Xi YH, Li HZ, Zhang WH, Wang LN, Zhang L, Lin Y, Bai SZ, Li HX, Wu LY, Wang R, Xu CQ. The functional expression of calcium-sensing receptor in the differentiated THP-1 cells. Mol Cell Biochem 2010;342:233-40. [PMID: 20473557 DOI: 10.1007/s11010-010-0489-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
35 Lafyatis R, Farina A. New insights into the mechanisms of innate immune receptor signalling in fibrosis. Open Rheumatol J 2012;6:72-9. [PMID: 22802904 DOI: 10.2174/1874312901206010072] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
36 Lattanzio SM. The gadolinium hypothesis for fibromyalgia and unexplained widespread chronic pain. Med Hypotheses 2019;129:109240. [PMID: 31371082 DOI: 10.1016/j.mehy.2019.109240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014;69:661-668. [PMID: 24582176 DOI: 10.1016/j.crad.2014.01.003] [Cited by in Crossref: 78] [Cited by in F6Publishing: 56] [Article Influence: 9.8] [Reference Citation Analysis]
38 Schieren G, Gambichler T, Skrygan M, Burkert B, Altmeyer P, Rump LC, Kreuter A. Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions. Am J Kidney Dis 2010;55:1040-9. [PMID: 20430497 DOI: 10.1053/j.ajkd.2010.01.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
39 Newton BB, Jimenez SA. Mechanism of NSF: New evidence challenging the prevailing theory. J Magn Reson Imaging 2009;30:1277-83. [PMID: 19937925 DOI: 10.1002/jmri.21980] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
40 Wermuth PJ, Jimenez SA. The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases. Clin Transl Med. 2015;4:2. [PMID: 25852818 DOI: 10.1186/s40169-015-0047-4] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 11.9] [Reference Citation Analysis]
41 Schmidt-Lauber C, Bossaller L, Abujudeh HH, Vladimer GI, Christ A, Fitzgerald KA, Latz E, Gravallese EM, Marshak-Rothstein A, Kay J. Gadolinium-based compounds induce NLRP3-dependent IL-1β production and peritoneal inflammation. Ann Rheum Dis 2015;74:2062-9. [PMID: 24914072 DOI: 10.1136/annrheumdis-2013-204900] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
42 Wermuth PJ, Jimenez SA. Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents. Clin Exp Immunol 2014;175:113-25. [PMID: 24111526 DOI: 10.1111/cei.12211] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
43 Piera-Velazquez S, Louneva N, Fertala J, Wermuth PJ, Del Galdo F, Jimenez SA. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69:2017-23. [PMID: 20570839 DOI: 10.1136/ard.2009.127761] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
44 Riser BL, Barnes JL, Varani J. Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer. J Cell Commun Signal 2015;9:327-39. [PMID: 26698861 DOI: 10.1007/s12079-015-0309-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
45 Wang Q, Cheng F, Ma TT, Xiong HY, Li ZW, Xie CL, Liu CY, Tu ZG. Interleukin-12 inhibits the hepatocellular carcinoma growth by inducing macrophage polarization to the M1-like phenotype through downregulation of Stat-3. Mol Cell Biochem. 2016;415:157-168. [PMID: 27003285 DOI: 10.1007/s11010-016-2687-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
46 Cheng Z, Thorek DL, Tsourkas A. Porous Polymersomes with Encapsulated Gd-labeled Dendrimers as Highly Efficient MRI Contrast Agents. Adv Funct Mater 2009;19:3753-9. [PMID: 23293575 DOI: 10.1002/adfm.200901253] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 5.8] [Reference Citation Analysis]
47 Macarak EJ, Lotto CE, Koganti D, Jin X, Wermuth PJ, Olsson A, Montgomery M, Rosenbloom J. Trametinib prevents mesothelial-mesenchymal transition and ameliorates abdominal adhesion formation. Journal of Surgical Research 2018;227:198-210. [DOI: 10.1016/j.jss.2018.02.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
48 Meng H, Grosse-Wortmann L. Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice. J Cardiovasc Magn Reson 2012;14:56. [PMID: 22871150 DOI: 10.1186/1532-429X-14-56] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
49 Del Galdo F, Wermuth PJ, Addya S, Fortina P, Jimenez SA. NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69:2024-33. [PMID: 20959327 DOI: 10.1136/ard.2010.134858] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
50 Wiesinger B, Kehlbach R, Hemsen J, Bebin J, Bantleon R, Schwenzer N, Spira D, Claussen CD, Wiskirchen J. Effects of magnetic resonance imaging contrast agents on human umbilical vein endothelial cells and evaluation of magnetic resonance imaging contrast media-triggered transforming growth factor-beta induction in dermal fibroblasts (HSF) as a model for nephrogenic systemic fibrosis. Invest Radiol 2011;46:71-6. [PMID: 21139503 DOI: 10.1097/RLI.0b013e31820218e9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
51 Idée JM, Port M, Dencausse A, Lancelot E, Corot C. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 2009;47:855-69, vii. [PMID: 19744600 DOI: 10.1016/j.rcl.2009.06.006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 5.0] [Reference Citation Analysis]
52 Riser BL, Bhagavathula N, Perone P, Garchow K, Xu Y, Fisher GJ, Najmabadi F, Attili D, Varani J. Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis. J Cell Commun Signal 2012;6:97-105. [PMID: 22648571 DOI: 10.1007/s12079-012-0164-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
53 Fretellier N, Idée JM, Dencausse A, Karroum O, Guerret S, Poveda N, Jestin G, Factor C, Raynal I, Zamia P, Port M, Corot C. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol 2011;46:292-300. [PMID: 21263333 DOI: 10.1097/RLI.0b013e3182056ccf] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
54 Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 2010;256:735-43. [PMID: 20663970 DOI: 10.1148/radiol.10091131] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]